SOURCE: DNAPrint Genomics, Inc.

November 08, 2005 07:00 ET

DNAPrint Pharmaceuticals to Combine Computer Modeling With Genetics to Improve Drug Development

SARASOTA, FL -- (MARKET WIRE) -- November 8, 2005 -- DNAPrint™ genomics, Inc. (OTC BB: DNAG) today announced that DNAPrint Pharmaceuticals, Inc.'s Computational Biology Division, which was recently acquired from Kenna Technologies, Inc., is preparing to launch its services contract business for the pharmaceutical and biotechnology industries.

By incorporating DNAPrint's pharmacogenomics contract services with those of the Computational Biology Division, the end result will be a unique solution for optimizing clinical trials. DNAPrint will demonstrate to drug developers that they can learn more about a new drug's patient benefit as well as an optimum dosing regimen.

The computational biology scientists at DNAPrint Pharmaceuticals have developed a system for analyzing complex biological processes. "Our offering is pragmatic," says Dr. Barbara Handelin, General Manager of Computational Biology. "Even with an imperfect understanding of disease and human physiology, we have shown that we can create highly predictive models that improve the understanding of researchers. We are especially excited to demonstrate to potential clients how modeling can work synergistically with genetic studies of drug response."

DNAPrint genomics utilizes a proprietary technology that measures variations among patient populations that relate to their responses to drugs. The combination of the two technologies will assist developers of pharmaceutical products in identifying important patient factors that impact how a specific drug will affect different groups of patients. Some of these factors are inborn, such as genetic markers; others are identified by the Company's computer simulations, which will be inherent to the role of the drug in the disease under treatment. The Company will also help identify genetic and other patient factors predisposing patients to toxic side effects.

DNAPrint also uses simulations to model the molecular and cellular effects of a drug candidate so that researchers can ask many more "what if" questions about dose levels and scheduling as opposed to actual human or animal studies. These simulations then guide the design of actual clinical trials with advanced "intelligence" about the likely outcomes. The likelihood of successful trials, targeted to the right patients with an effective dosing regimen is greatly enhanced; and could lead to reduced time and costs of clinical studies.

"We invite everyone to use our services," said Hector J. Gomez, M.D., Ph.D., DNAPrint's Chairman and Chief Medical Officer. "We believe that bringing computer modeling and genetics together is a natural fit for optimizing drug discovery and development. These are independent approaches that together start to improve preclinical and clinical development from strictly empirical medicinal chemistry trials to mechanistically driven human biology studies."

"Simply put, DNAPrint will utilize computational modeling to develop drugs more efficiently," said DNAPrint President and Chief Executive Officer Richard Gabriel. "It will play a valuable role in any company's efforts to pursue the development of drugs which maximize efficacy and minimize side effects by tailoring medications for specific individuals and well-defined population sectors."

About DNAPrint

DNAPrint™ genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services focused on drug development, pharmacogenomic diagnostic tests, forensics technology and consumer genetic tests. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, is responsible for the development of diagnostic tests and theranostic products (drug/test combination) and also provides Computational Biology and Pharmacogenomics Services. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (end stage renal disease). Currently in pre-clinical development, PT-401 will be targeted to patients with a genetic profile indicating their propensity to have the best clinical response. DNAPrint's family of products for the law enforcement forensics and consumer markets include DNAWITNESS™, RETINOME™, ANCESTRYbyDNA™ and EURO-DNA™.

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.

Contact Information

  • Company Contact:
    Richard Gabriel
    CEO and President
    941 366-3400

    Ron Stabiner
    The Wall Street Group, Inc.
    212-888-4848